Daewon 에볼루션 바카라 completes Phase 1 clinical trials in Vietnam for domestically produced novel drug Pelubi and combination candidate DW1021

[by Kang, In Hyo] Daewon Pharmaceutical announced on August 21 that it has successfully completed Phase 1 clinical trials in Vietnam for its investigational compound analgesic, ‘DW1021,’ combining Pelubi Tablets and Tramadol, Korea's 12th novel drug. According to the company, this marks the first Phase 1 clinical trial conducted in Vietnam by a Korean pharmaceutical firm.

The company highlighted that the clinical trial was carried out with backing from the Ministry of Trade, Industry and Energy's program, ‘Development of Improved Pharmaceutical Products Based on Formulation Technology for Global Market Entry.’ It emphasized that the study not only lays the groundwork for entry into the Vietnamese market but also forms a key component of its strategy to expand into pharmerging markets worldwide, particularly across Southeast Asia.

The initiative is designed to facilitate the global expansion of ‘technology-based medicines (TBMs),’ which are distinguished from conventional products through advanced formulation technologies and enhanced compliance. Korean pharmaceutical and biotechnology firms have long faced challenges in penetrating pharmerging markets, largely due to the absence of clear regulatory frameworks and approval pathways for TBMs, as well as limited access to local networks and infrastructure.

Building on the success of Pelubi, Korea's 12th novel drug and the country’s most prescribed non-steroidal anti-inflammatory drug (NSAID), Daewon Pharmaceutical has embarked on the development of a tramadol combination therapy aimed at delivering stronger pain relief. DW1021 combines the two ingredients through an ionic bond to maximize synergistic effects. This combination enables effective analgesic effects at a reduced tramadol dosage, thereby lowering overall tramadol use and minimizing associated side effects.

The clinical trial, approved by the Vietnamese Ministry of Health (MoH), started at the Center for Clinical Trials and Bioequivalence (HPMP) at the Hai Phong University of Medicine and Pharmacy. Conducted in Vietnamese adults, the study assessed the bioavailability and dietary influence of DW1021, confirming similar bioavailability to those observed in Korean participants. Daewon 에볼루션 바카라 further noted that, despite being a sustained-release formulation, the candidate exhibited no dietary influence and demonstrated excellent tolerability and safety.

Following the successful completion of the phase 1 clinical trial for DW1021, Daewon Pharmaceutical announced plans to carry out follow-up clinical studies in Vietnam with the goal of securing marketing approval. "This clinical trial marks an important milestone in our efforts to enter emerging markets, including Southeast Asia. We will actively promote the strengths of Korea’s domestically developed new drugs and set a successful precedent for global expansion," a Daewon Pharmaceutical official stated.

Conversely, the 에볼루션 바카라 market in the six major Southeast Asian countries (Indonesia, Vietnam, the Philippines, Thailand, Malaysia, and Singapore) was projected to reach approximately USD 20 billion (KRW 26 trillion) by 2023. Within this, Vietnam's 에볼루션 바카라 market is valued at around USD 7 billion, having recorded an average annual growth rate of 7.3% over the past 10 years, underscoring its rapid expansion.